FDA Grants Fast Track Designation to Dilanubicel for Allogeneic Cord Blood Transplant Patients
The FDA has granted a fast track designation to Nohla Therapeutics’ dilanubicel (NLA101) for patients with high-risk hematologic malignancies receiving an allogeneic cord blood transplant.
Pitolisant Receives FDA Breakthrough Therapy and Fast Track Designations
Harmony Biosciences, LLC, announced that the FDA has granted Breakthrough Therapy and Fast Track designations to its product, pitolisant, for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.
The Effects of Dietary Fat and Carbohydrate on Metabolic Health
A new meta-analysis of 102 randomized controlled diet trials found that consumption of polyunsaturated fat instead of carbohydrate or saturated fat reduces blood sugar levels and insulin resistance while also increasing the body’s ability to make insulin.
Fasting Blood Glucose and Pancreatic Cancer: Possible Link
January 19th 2015The incidence and mortality of pancreatic adenocarcinoma, the fourth leading cause of cancer deaths in the United States, are both on the rise. Globally, the disease is responsible for 227,000 deaths annually. Researchers from the National Taiwan University College of Medicine recently published a meta-analysis that demonstrated a dose-response relationship between fasting blood glucose levels and pancreatic cancer risk. They also examined the link between prediabetes and pancreatic cancer risk.